Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
‘President of peace’: Trump tapped for Nobel Prize...
Trump’s push for Putin-Zelenskyy talks hinges on Kremlin’s...
Israel eliminates Gaza terrorist who took part in...
White House rejects ‘blank checks’ for Ukraine, presses...
Justice Barrett teases new memoir in abrupt conference...
Schiff launches legal defense fund in response to...
Gabbard removes clearances from 37 officials at Trump’s...
Russia launches largest attack on Ukraine this month...
Trump slams mail-in ballots as corrupt, but may...
I made memes for the White House. Here’s...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Investing

68Ga-RAD 301 (68Ga-Trivehexin) Demonstrates Strong Potential for Imaging of αvβ6-Integrin Expression in Pancreatic Cancer Patients

by admin November 18, 2024
November 18, 2024
68Ga-RAD 301 (68Ga-Trivehexin) Demonstrates Strong Potential for Imaging of αvβ6-Integrin Expression in Pancreatic Cancer Patients

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that a clinical study featuring 68Ga-Trivehexin (68Ga-RAD 301), conducted by Dr. Rehm and colleagues from the Technische Universität Dresden, has now been published in Frontiers in Nuclear Medicine.

  • Clinical study of 44 patients published in ‘Frontiers in Nuclear Medicine’ by Dr Jana Rehm and colleagues demonstrated that Ga68-labelled RAD 301 is a safe and suitable agent for imaging in pancreatic cancer.
  • Results indicate that the primary tumor and metastases were well-visualized with a high tumor-to-background ratio.
  • A Phase I imaging trial (NCT05799274) with 68Ga-RAD 301 in pancreatic cancer patients to assess the safety and imaging characteristics of RAD 301 is currently ongoing.

The paper, entitled “αvβ6-integrin targeted PET/CT imaging in pancreatic cancer patients using 68Ga-Trivehexin”1, describes the clinical results of a retrospective study of the biokinetics of 68Ga- RAD 301 in pancreatic cancer patients. This 44-patient study is reported as the largest cohort of individuals imaged with RAD 301 with any tracer.

The primary tumor, as well as metastases in the liver, lymph nodes, peritoneum, lung, bone, spleen, pleural cavity, and soft tissues, were visualized with a high tumor-to-background ratio. With no adverse events recorded, the findings indicate that RAD 301 is a suitable and safe diagnostic agent for imaging αvβ6-integrin expression in pancreatic cancer.

RAD 301 is a peptide that targets αvβ6-integrin, a cellular marker for tumor invasion and metastatic growth, the expression of which correlates with decreased survival in several carcinomas, particularly pancreatic. The αvβ6-integrin receptor is found in high density on most pancreatic carcinoma and head and neck squamous carcinoma cells, making it an attractive potential diagnostic and therapeutic target in Pancreatic Ductal Adenocarcinoma (PDAC) and Head-and-Neck Squamous Cell Carcinoma2.

A Phase I imaging trial (NCT05799274) with 68Ga-RAD 301 in PDAC patients is currently being conducted at the Montefiore Medical Center, Albert Eistein College of Medicine, NY, USA. The study will assess the safety, radiation dosimetry and imaging characteristics of RAD 301 in patients with advanced PDAC3. In May 2023, the FDA granted Radiopharm with an Orphan Drug Designation (ODD) for RAD 301 in pancreatic cancer.

“Current imaging standards of care for the detection of PDAC have significant limitations, making this one of the highest areas of unmet medical need and posing a major challenge for healthcare providers in imaging PDAC patients,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. “These findings reinforce the clinical potential of RAD 301 as an imaging agent for the more sensitive and selective detection of pancreatic cancer and its metastases, ultimately advancing PDAC patient management.”

Click here for the full ASX Release

This post appeared first on investingnews.com

previous post
ISLA-101 Phase 2a/b PROTECT Clinical Trial Progress Update
next post
Fetterman calls out ‘UN’s rank, pervasive antisemitism,’ says he looks forward to confirming Elise Stefanik

You may also like

Awalé Uncovers 3.5km Gold Footprint on 100%-Owned Ground...

October 22, 2024

Lode Gold Identifies New High Priority RIRGS Target...

October 15, 2024

Zinc Price 2024 Year-End Review

January 14, 2025

Canada Makes Tech Leadership Moves: Axl Launches, Carney...

June 23, 2025

Osisko Metals: Leading the Charge in Base Metal...

November 22, 2024

Charbone Hydrogene annonce les resultats financiers T1 2025

May 30, 2025

Prismo Metals Updates Exploration at Hot Breccia

February 28, 2025

Chariot Corporation Ltd (ASX: CC9) – Trading Halt

October 17, 2024

Crypto Market Recap: Strategy Eyes US$1 Billion Capital...

June 7, 2025

Finlay Minerals stakes the JJB Property – within...

April 23, 2025

Recent Posts

  • ‘President of peace’: Trump tapped for Nobel Prize amid talks to end Russia-Ukraine war
  • Trump’s push for Putin-Zelenskyy talks hinges on Kremlin’s conditions
  • Israel eliminates Gaza terrorist who took part in October attack on kibbutz, took Yarden Bibas hostage
  • White House rejects ‘blank checks’ for Ukraine, presses NATO to shoulder costs
  • Justice Barrett teases new memoir in abrupt conference exit

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (881)
    • Investing (2,793)
    • Politics (3,430)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 Sightful Invest. All Rights Reserved.